Covid-19. COVID-19, Virus Identified
Conditions
Interventions
Intervention 1: Intervention group: hydroxychloroquine Ruzdarou 200mg
This group take 2 hydroxychloroquine tablet (400 mg) for the first day and From the second day, take one tablet (200 mg) daily for two weeks. Intervention 2: Control group: Domestic quarantine for 14
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Clinical symptoms including: Fever Shortness of breath Cough Positive Covide test Typical symptoms on a CT scan
Exclusion criteria
Exclusion criteria: Hypersensitivity reaction to Hydroxychloroquine Already taking Chloroquine or Hydroxychloroquine Cardiac Arrhythmia Already taking drugs that prolong QT Decreased renal function in stages 4 and 5.(GFR <30) The history of enzymatic disorders caused by some drugs that result in red blood cell lysis (G6PD). The history of Retinopathy Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of incubation time. Timepoint: Daily for 14 days. Method of measurement: Participants' clinical status.;Reducing the incidence of Symptomatic respiratory disease. Timepoint: 14 days after taking hydroxychloroquine. Method of measurement: CT-scan test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Ebrahim Khamseh
The Institute of Endocrinology and Metabolism Research and Training Center
Outcome results
None listed